Ambulatory Liver Fat Monitoring in Patients With Non-alcoholic Fatty Liver Disease

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
Non-alcoholic fatty liver disease (NAFLD) affects 25% of the global population and causes serious complications, including cirrhosis, hepatocellular carcinoma or mortality. Unfortunately, there are not yet any approved drugs to treatment NAFLD. The only effective means to improve NAFLD is by weight reduction via lifestyle modifications, i.e., diet and physical activity. Most NAFLD patients lack the motivation to initiate and maintain lifestyle modifications. The investigators hypothesize that ambulatory monitoring of liver fat can help NAFLD patients lose more liver fat by motivating them to gain a sense of control over their condition.
Epistemonikos ID: da7f954c9c144e56d65e02d45ed5e7cb20879727
First added on: Feb 19, 2024